Related Experiment Video
Updated: Nov 30, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Association between statin use and cognitive function: A systematic review of randomized clinical trials and
Anish Adhikari1, Swetapadma Tripathy2, Sarah Chuzi3
1Albany Medical Center, Albany, NY, USA.
Insights
Statin use in individuals over 60 years old is not linked to cognitive impairment or dementia. A systematic review found no adverse cognitive effects, supporting continued statin therapy for guideline-directed indications.
Area of Science:
- Gerontology and Cognitive Health
- Pharmacology and Therapeutics
- Evidence-Based Medicine
Background:
- A 2012 black box warning linked statin use to cognitive impairment, potentially discouraging appropriate patient use.
- Large-scale studies have not substantiated an increased risk of cognitive decline with statin therapy.
- Concerns persist regarding the cognitive safety of statins, particularly in older adults.
Purpose of the Study:
- To conduct an up-to-date systematic review of randomized controlled trials (RCTs) and prospective observational studies.
- To examine the association between statin use and cognitive status in individuals aged 60 years and older.
- To provide evidence-based information to address concerns raised by the black box warning.
Main Methods:
- Systematic review of MEDLINE, EMBASE, and Cochrane databases up to October 2019.
- Inclusion of 3 randomized controlled trials (RCTs) and 21 prospective observational studies.
- Analysis of data from 1,404,459 participants aged ≥60 years.
Main Results:
- All 3 RCTs (3.2–5.6 years follow-up) found no significant association between statin use and adverse cognitive effects.
- Observational studies (3–15 years follow-up) showed mixed results, with 10 indicating reduced dementia incidence and none showing increased risk.
- No evidence of adverse cognitive effects, including dementia incidence or global cognitive decline, was found in individuals aged ≥60 years.
Conclusions:
- Statin use in individuals aged 60 years and older is not associated with cognitive impairment or dementia.
- The findings do not support the concerns raised by the 2012 black box warning regarding cognitive side effects.
- Further research with longer follow-up periods is recommended to comprehensively assess the long-term cognitive impact of statins.
Abstract:
The US Food and Drug Administration issued a black box warning in 2012 regarding the association of statin use with cognitive impairment. This may deter patients and practitioners from using statins for guideline-directed indications. Large studies have not shown an increase in cognitive impairment with statin use. MEDLINE, EMBASE, and Cochrane databases were searched up to October 2019. We present an up-to-date systematic review of randomized controlled trials (RCTs) and prospective observational studies examining the association between statin use and cognitive status in a population aged ≥60 years. Twenty-four studies with 1,404,459 participants were included in the review. Twenty-one were prospective observational studies, and 3 were RCTs. All 3 RCTs, which ranged from 3.2 to 5.6 years of follow-up, showed no significant association between statin use and adverse cognitive effects (odds ratio [OR] 1.03 [0.82-1.30]) and (OR 1.0 [0.61-1.65]). The mean difference in the Mini-Mental State Examination was insignificant (0.06 [-0.04 to 0.16]) in the third RCT. The follow-up for observational studies ranged from 3 to 15 years. Ten observational studies showed reduced incidence of dementia. Seven showed no association with incident dementia. Three studies showed decline in cognition was similar, whereas one showed slower decline with statin use. There was no evidence of adverse cognitive effects, including incidence of dementia, deterioration in global cognition, or specific cognitive domains associated with statin use in individuals aged ≥60 years. Future studies should examine this association in studies with longer follow-up periods.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:26Atherosclerosis III: Management
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...